Fig. 6

Incidence of any adverse events in the comparison of selective COX-2 inhibitors versus placebo in patients with ankylosing spondylitis: meta-analysis of three randomized clinical trials. Subtitle: (1) Celecoxib 400 mg vs placebo. (2) Celecoxib 200 mg vs placebo. (3) Etoricoxib 90 mg vs placebo